Healthcare provider profile · identity verified

Rahil H Shaikh, MD

Internal Medicine · BOLINGBROOK, IL · NPI 1639467897

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	606	33
Eliquis	Apixaban	338	20
Quetiapine Fumarate	Quetiapine Fumarate	327	16
Gabapentin	Gabapentin	279	22
Amlodipine Besylate	Amlodipine Besylate	270	20
Carvedilol	Carvedilol	246	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	235	15
Losartan Potassium	Losartan Potassium	212	suppressed
Metformin Hcl	Metformin Hcl	212	suppressed
Metoprolol Succinate	Metoprolol Succinate	203	14
Clopidogrel	Clopidogrel Bisulfate	184	suppressed
Sertraline Hcl	Sertraline Hcl	175	11
Levetiracetam	Levetiracetam	166	suppressed
Omeprazole	Omeprazole	165	11
Memantine Hcl	Memantine Hcl	160	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	157	suppressed
Furosemide	Furosemide	157	17
Mirtazapine	Mirtazapine	150	12
Famotidine	Famotidine	123	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	119	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	116	13
Allopurinol	Allopurinol	114	suppressed
Potassium Chloride	Potassium Chloride	111	13
Amiodarone Hcl	Amiodarone Hcl	108	suppressed
Hydralazine Hcl	Hydralazine Hcl	95	suppressed
Levothyroxine Sodium	Levothyroxine Sodium	88	suppressed
Simvastatin	Simvastatin	87	suppressed
Donepezil Hcl	Donepezil Hcl	86	suppressed
Trazodone Hcl	Trazodone Hcl	86	11
Bumetanide	Bumetanide	78	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	71	suppressed
Jardiance	Empagliflozin	70	suppressed
Baclofen	Baclofen	54	suppressed
Glycopyrrolate	Glycopyrrolate	54	suppressed
Renvela	Sevelamer Carbonate	51	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	50	11
Sucralfate	Sucralfate	50	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	49	suppressed
Labetalol Hcl	Labetalol Hcl	45	suppressed
Januvia	Sitagliptin Phosphate	42	suppressed
Lovastatin	Lovastatin	41	suppressed
Buspirone Hcl	Buspirone Hcl	40	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	39	suppressed
Lisinopril	Lisinopril	39	suppressed
Torsemide	Torsemide	37	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	34	suppressed
Metolazone	Metolazone	34	suppressed
Prednisone	Prednisone	33	suppressed
Midodrine Hcl	Midodrine Hcl	32	suppressed
Duloxetine Hcl	Duloxetine Hcl	31	suppressed
Naproxen	Naproxen	31	suppressed
Tizanidine Hcl	Tizanidine Hcl	31	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	30	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	30	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	29	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	28	suppressed
Lubiprostone	Lubiprostone	26	suppressed
Clonidine Hcl	Clonidine Hcl	25	suppressed
Diltiazem Hcl	Diltiazem Hcl	25	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	25	suppressed
Xarelto	Rivaroxaban	25	suppressed
Haloperidol	Haloperidol	22	suppressed
Nifedipine Er	Nifedipine	22	suppressed
Humalog Kwikpen U-100	Insulin Lispro	21	suppressed
Calcium Acetate	Calcium Acetate	20	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	20	suppressed
Ondansetron Hcl	Ondansetron Hcl	20	suppressed
Risperidone	Risperidone	20	suppressed
Bupropion Xl	Bupropion Hcl	18	suppressed
Scopolamine	Scopolamine	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Irbesartan	Irbesartan	17	suppressed
Nystatin	Nystatin	17	suppressed
Olanzapine	Olanzapine	17	suppressed
Spironolactone	Spironolactone	17	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	17	suppressed
Divalproex Sodium	Divalproex Sodium	15	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	14	suppressed
Meloxicam	Meloxicam	14	suppressed
Aripiprazole	Aripiprazole	13	suppressed
Oxcarbazepine	Oxcarbazepine	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	12	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error